EuroBiotech Report—Healx and Abalos raise cash, Ipsen bags Blueprint drug, Gilead and ReNeuron

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start with Healx, an AI-enabled biotech with big plans for the $56 million series B round it raised this week. Armed with the money, Healx plans to start 40 rare disease programs while advancing existing assets into the clinic. Abalos Therapeutics also raised money, reeling in €12 million from investors including Boehringer Ingelheim's VC wing to develop anti-cancer viruses. Elsewhere, Ipsen added another treatment for fibrodysplasia ossificans progressiva to its pipeline through a deal with Blueprint Medicines. Gilead Sciences and Galapagos shared a 52-week update on filgotinib. ReNeuron presented data on its stem cell vision loss therapy. And more. — Nick Taylor
 
1. Healx raises $56M to launch 40 rare disease R&D programs

Healx has raised $56 million (€51 million) to launch 40 rare disease programs while taking some of its existing assets into the clinic. The ambitious target is enabled by an AI drug discovery platform Healx thinks gives it a scalability that has more in common with tech than biotech. 
 
2. Boehringer's VC wing backs anti-cancer virus startup

Abalos Therapeutics has raised €12 million ($13 million) to discover and develop cancer drugs based on an arenavirus strain. The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans. 
 
3. Ipsen bags Blueprint drug to move deeper into ultra-rare disease

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Ipsen has struck a deal with Blueprint Medicines to add another treatment for fibrodysplasia ossificans progressiva (FOP) to its rare disease pipeline. The backloaded, $535 million (€485 million) deal comes months after Ipsen paid $1 billion to buy Clementia Pharmaceuticals for an FOP therapy. 
 
4. Gilead, Galapagos share 52-week update on filgotinib

Gilead Sciences and Galapagos have said 52-week phase 3 data for JAK1 inhibitor filgotinib in rheumatoid arthritis are consistent with earlier readouts. The update comes as Gilead prepares to make the case that filgotinib is safe and effective to the FDA.  

5. ReNeuron shares clinical data on stem cell vision loss therapy

ReNeuron has presented detailed data from a phase 1/2a clinical trial of its stem cell treatment for retinitis pigmentosa. Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month, but the biotech argued the detailed results are positive for its prospects. 
 
And more articles of note>> 

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.